Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Grifols S.A. (GRFS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 13,990,982
  • Shares Outstanding, K 682,820
  • Annual Sales, $ 4,482 M
  • Annual Income, $ 603,600 K
  • 36-Month Beta 0.97
  • Price/Sales 3.15
  • Price/Cash Flow 15.47
  • Price/Book 3.58

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.92 +2.86%
on 07/27/17
21.09 -2.84%
on 08/01/17
-0.39 (-1.87%)
since 07/14/17
3-Month
19.92 +2.86%
on 07/27/17
22.83 -10.25%
on 06/22/17
-1.29 (-5.92%)
since 05/16/17
52-Week
14.27 +43.59%
on 10/31/16
22.83 -10.25%
on 06/22/17
+3.93 (+23.73%)
since 08/16/16

Most Recent Stories

More News
Select American Red Cross Blood Donations Screened for Babesia Parasite Using Grifols' Procleix Babesia Assay Under an Investigational New Drug Protocol

Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, announced today that the American...

GRFS : 20.49 (-0.97%)
GRF : 7.93 (+0.25%)
Grifols adds ID RHD XT diagnostic kit to its molecular portfolio

- Grifols receives CE mark approval for ID RHD XT

GRFS : 20.49 (-0.97%)
Grifols Continues to Strengthen its Diagnostic Division by Launching New Global Testing Services for the Measurement of Biological Drug Levels and Anti-Drug Immune Response in Blood Samples

Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), a leading global producer of plasma-derived medicines, and a leader in the development of innovative diagnostic solutions, is expanding its Texas-based...

GRFS : 20.49 (-0.97%)
GRF : 7.93 (+0.25%)
Should Value Investors Consider Grifols (GRFS) Stock Right Now?

Is Grifols a great pick from the value investor's perspective right now? Read on to know more.

GRFS : 20.49 (-0.97%)
Daily Technical Summary Reports on Biotech Stocks -- Illumina, Navidea Biopharma, Grifols, and Intercept Pharma

DailyStockTracker.com today reviews Illumina Inc. (NASDAQ: ILMN), Navidea Biopharmaceuticals Inc (NYSE MKT: NAVB), Grifols S.A. (NASDAQ: GRFS), and Intercept Pharmaceuticals Inc. (NASDAQ: ICPT). According...

ILMN : 194.15 (+0.12%)
GRFS : 20.49 (-0.97%)
NAVB : 0.41 (unch)
ICPT : 105.47 (+1.33%)
Grifols Makes Procleix Zika Virus Assay Available for Screening Blood Donations to Countries Accepting CE Mark

- Grifols strengthens its Procleix portfolio with the CE marking for Procleix Zika Virus Assay

GRFS : 20.49 (-0.97%)
GRF : 7.93 (+0.25%)
Investigational New Drug Application is Now Effective for Babesia Screening in Blood Donations Using Grifols Procleix Panther System in the US

-- Test is designed to detect the presence in whole blood, of the four clinically relevant species of Babesia (B. microti, B. duncani, B. divergens, and B. venatorum), a parasite that can be transmitted...

GRFS : 20.49 (-0.97%)
GRF : 7.93 (+0.25%)
VIVUS (VVUS) Loss Narrower than Expected, Revenues Up Y/Y

VIVUS Inc. (VVUS) reported a loss of 1 cent per share in the first quarter of 2017, which was narrower than a loss of 12 cents in the year-ago period as well as the Zacks Consensus Estimate of a loss of...

VVUS : 1.02 (+0.99%)
GRFS : 20.49 (-0.97%)
INFI : 1.11 (+2.78%)
SNY : 48.43 (+1.25%)
Akebia Therapeutics (AKBA) Shows Strength: Stock Up 5.8%

Akebia Therapeutics, Inc. (AKBA) shares rose almost 6% in the last trading session.

AKBA : 15.25 (+0.59%)
GRFS : 20.49 (-0.97%)
Glaxo (GSK) Reports In-Line Q1 Earnings, Reiterates View

GlaxoSmithKline plc's (GSK) first quarter results came roughly in line with expectations. Glaxo reported first-quarter 2017 core earnings of 62 cents per American Depositary Share (ADS), in line with...

MYL : 30.47 (+1.13%)
GRFS : 20.49 (-0.97%)
INFI : 1.11 (+2.78%)
GSK : 39.24 (+0.74%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More

Business Summary

Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience...

See More

Support & Resistance

2nd Resistance Point 21.00
1st Resistance Point 20.75
Last Price 20.49
1st Support Level 20.35
2nd Support Level 20.20

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.